Ingredient comparison

Exenatide vs Liraglutide

Last updated

Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.

Exenatide vs Liraglutide: lowest prices now

  • Liraglutide: lowest FDA-approved

    Amazon Pharmacy

    $1,230.30 per 5 pens · about $1230 per 30 days

  • Liraglutide: lowest compounded on a monthly plan, not FDA-approved

    Henry Meds

    $179/mo

Every cash quote was checked on or after .Data feeds · Nov 16, 2026 UTC
Exenatide vs Liraglutide: overview
CompareExenatideLiraglutide
What it is for

FDA-approved for

  • Type 2 diabetes

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
Brands
Route & frequency

Subcutaneous injection

Twice daily (Byetta); once weekly (Bydureon BCise)

Subcutaneous injection

Once daily

FDA shortage report

National reporting does not confirm stock at your pharmacy.

Coverage & source records
In shortage

National reporting does not confirm stock at your pharmacy.

Coverage & source records
What was tested together

Direct comparative evidence

No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.

Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Exenatide vs Liraglutide: sourced cash quotes
CompareExenatideLiraglutide
Advertised entry price
~$422 per pen (goodrx.com/exenatide)

Generic exenatide (Amneal)

GoodRx

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Third-party reported price

Days of supply not on record; not ranked per 30 days.

Checked on goodrx.com

Price conditions

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock.

from $349/mo (healifynow.com/saxenda)

Saxenda via HealifyNow

HealifyNow

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

Billed per month; days of supply not on record, so ordered as four weekly doses.

Checked on healifynow.com

Price conditions

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

A starting price: the page does not say what the figure includes or how it changes with the dose; the page prices it per month with no contracts. Its pages also list "Liraglutide From $149/mo" without saying which kind of liraglutide it is. FDA-approved product.

At the named trial dose

No sourced quote tracked for this price basis.

~$372/mo (goodrx.com/liraglutide-saxenda)

Generic liraglutide 3 mg pens (Saxenda generic), GoodRx coupon

At 3 mg

GoodRx

Published price at 3 mg

Third-party reported price

30-day supply (dailymed.nlm.nih.gov)

$372.45 per 30 days at this quoted rate

Checked on goodrx.com

Price conditions

Published price at 3 mg

GoodRx lists this liraglutide (Saxenda) only as a generic; its price is for one carton of five 18 mg/3 mL pens. Prices vary by pharmacy.

Five pens hold 90 mg: 30 days at the 3 mg daily dose.

30-day supply

Every offerSee the offerAll 29 offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Exenatide vs Liraglutide: individual trial outcomes
CompareExenatideLiraglutide
Weight change
≈−4% (diabetesjournals.org/care/article/33/6/1255/27340/DURATION-1-Exenatide-Once-Weekly-Produces) (-4.1 kg (~4% of the 102 kg baseline) at 52 wks · DURATION-1 · 2 mg weekly (Bydureon))

-4.1 kg (~4% of the 102 kg baseline) at 52 wks

DURATION-1 (diabetesjournals.org)

2 mg weekly (Bydureon)

Approximation from kilograms; see trial methods

Study context

The oldest GLP-1; a diabetes trial with a modest weight effect.

−8% (nejm.org/doi/full/10.1056/NEJMoa1411892) (-8.0% at 56 wks · SCALE Obesity · 3.0 mg daily (Saxenda))

-8.0% at 56 wks

SCALE Obesity (nejm.org)

3.0 mg daily (Saxenda)

Analysis not classified; see trial methods

HbA1c change (percentage points)
−1.9 pp (pubmed.ncbi.nlm.nih.gov/18782641) (-1.9% at 30 wks · DURATION-1 · HbA1c change in percentage points)

-1.9 percentage points at 30 wks

DURATION-1 (pubmed.ncbi.nlm.nih.gov)
−1.3 pp (doi.org/10.1001/jama.2015.9676) (-1.3% at 56 wks · SCALE Diabetes · HbA1c change in percentage points)

-1.3 percentage points at 56 wks

SCALE Diabetes (doi.org)
Adverse events

Stopped treatment for adverse events

3.9% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (3.9% discontinued for adverse reactions · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Reported nausea

8.2% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (Nausea in the drug arm · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Bydureon BCise FDA label (2 mg, type 2 diabetes)

from the FDA label adverse-reactions table (DURATION-1 does not cleanly report AE discontinuation); a diabetes population

Stopped treatment for adverse events

9.8% (accessdata.fda.gov/drugsatfda_docs/label/2014/206321orig1s000lbl.pdf) (9.8% vs 4.3% placebo (3.0 mg) · FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE))

Reported nausea

39.3% (accessdata.fda.gov/drugsatfda_docs/label/2014/206321orig1s000lbl.pdf) (Nausea in the drug arm · FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE))

FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE)

from the FDA Saxenda adverse-reactions table (the SCALE Obesity trial paper is paywalled); essentially identical to the trial's own ~9.9% / ~40% figures

From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Victoza1.8 mg from week 3about 13 hoursYes, 8None listed6,810
Saxenda3 mg from week 5about 13 hoursYes, 3None listedNone listed

How long each takes · Generics and patents · Who covers what

Check the product label

Approved uses & full records

Exenatide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

381 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record

Liraglutide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

522 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Is Exenatide or Liraglutide better for weight loss?

No trial on our list compared them directly. In separate trials: Exenatide -4.1 kg (~4% of the 102 kg baseline) at 52 wks in DURATION-1 (2 mg weekly (Bydureon)) (diabetesjournals.org); Liraglutide -8.0% at 56 wks in SCALE Obesity (3.0 mg daily (Saxenda)) (nejm.org). Separate trials enrolled different people for different lengths of time, so these figures cannot rank them.

Is Exenatide or Liraglutide safer?

We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Exenatide 3.9% discontinued for adverse reactions (Bydureon BCise FDA label (2 mg, type 2 diabetes)) (accessdata.fda.gov); Liraglutide 9.8% vs 4.3% placebo (3.0 mg) (FDA Saxenda label, pooled 3.0 mg obesity trials (SCALE)) (accessdata.fda.gov). Each FDA label lists its own warnings, and which ones matter depends on your health.

What Liraglutide dose is equivalent to Exenatide?

No FDA label sets a dose of Exenatide that equals a dose of Liraglutide, and we know of no trial that defines one. Switching is a prescriber's decision, and each label sets its own starting dose and steps.

Which costs less: Exenatide or Liraglutide?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Updated automatically

What changed for Exenatide and Liraglutide

  • TrialResults posted for a Liraglutide study: SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (clinicaltrials.gov/study/NCT04775082)
  • FDA labelFDA label updated: Liraglutide (Lupin Pharmaceuticals, Inc.), effective 2026-10-30 (api.fda.gov/drug/label.json)
  • FDA labelFDA label updated: liraglutide (Orbicular Pharmaceutical Technologies Private Limited), effective 2026-10-15 (api.fda.gov/drug/label.json)
  • FDA labelFDA label updated: Liraglutide (Orbicular Pharmaceutical Technologies Private Limited), effective 2026-10-15 (api.fda.gov/drug/label.json)
  • PriceGoodRx: Generic exenatide (Amneal) now ~$422 per pen (was ~$447 per pen) (read on goodrx.com)
  • PriceGoodRx: Generic liraglutide pens (Victoza generic), GoodRx coupon now ~$144 per 3 pens (was ~$102 per 2 pens) (read on goodrx.com)

Written from each source's own record as it changes. Every change on GLPcompare

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.